Kornimate/medical-research-clean huggingface dataset:
effects of peanut consumption on brain function

Conditions: Brain Vascular Function; Cerebral Blood Flow; Brain Insulin Sensitivity; Cognitive Performance

Summary: impaired brain vascular function precedes the development of reduced cognitive performance, while brain insulin-resistance is also associated with cognitive decline. peanut consumption has already been shown to beneficially affect cognitive performance. however, underlying mechanisms have not yet been established, while well-controlled trials on longer-term effects of peanuts on cognitive performance are highly needed. the hypothesis is that longer-term peanut consumption has beneficial effects on (regional) cerebral blood flow responses (primary outcome), which may relate to an improved cognitive performance (secondary outcome) in older men and women. important objectives are to investigate in older adults the effect of 16-week peanut consumption on (i) brain vascular function in cognitive-control brain areas, and (ii) brain insulin-sensitivity. we will also focus on changes in cognitive performance as assessed with a neuropsychological test battery (secondary objective). cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (mri)-perfusion method arterial spin labeling (asl).


Eligibility criteria:
inclusion criteria: * men and women, aged between 60-75 years * bmi between 20-35 kg/m2 * fasting plasma glucose \< 7.0 mmol/l * fasting serum total cholesterol \< 8.0 mmol/l * fasting serum triacylglycerol \< 4.5 mmol/l * systolic blood pressure \< 160 mmhg and diastolic blood pressure \< 100 mmhg * stable body weight (weight gain or loss \< 3 kg in the past three months) * willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study * no difficult venipuncture as evidenced during the screening visit exclusion criteria: * allergy or intolerance to peanuts * left-handedness * current smoker, or smoking cessation \< 12 months * diabetic patients * familial hypercholesterolemia * abuse of drugs * more than 3 alcoholic consumptions per day * use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators * use medication to treat blood pressure, lipid, or glucose metabolism * use of an investigational product within another biomedical intervention trial within the previous 1-month * severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis * active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident * contra-indications for mri imaging (e.g., pacemaker, surgical clips/material in body, metal splinter in eye, claustrophobia)
prevalence of oral side effects associated with chemo and radiotherapy for treating head and neck cancer

Conditions: Oral Complications of Chemotherapy and Head and Neck Radiation

Summary: a cross-sectional study will be conducted to report oral complications during chemo and radiotherapy treatment in case of patients diagnosed with head and neck cancer and the effect of theses oral side effects on patients' quality of life which will in turn allow the implication of preventive measures

the primary out come of this study is to report oral side effects associated with chemo and radiotherapy used for treating head and neck cancer .patient will be enrolled and data will be collected from the national institute of cancer in egypt. this will be done through filling the modified ( edmonton symptom assessment system) esas questionnaire used to asses different oral side effects in cancer patients. history taking and clinical examination will be done for each patient enrolled in the study after obtaining their consent form by the main investigator. each and every oral manifestations will be measured by a specific scale . the secondary outcome is identified as the assessment of the effect of oral complications on patients' quality of life which will be determined through completing uw-qol(university of washington-quality of life) questionnaire version 4.during the study, patient , treatment and tumor variable will be considered and documented .data collected form the patient and or from medical records will be saved and tabulated on computer for back up and finally statistically analyzed. a power analysis was designed to have adequate power to apply a statistical test of the research question regarding the degree to which oral adverse events can prevail among patients receiving chemotherapy or radiotherapy. according to the results of minhas, sadia, et al. -in which prevalence of oral adverse events was (92.6%)- and by adopting a confidence interval of (95%), a margin of error of (3%) with finite population correction; the predicted sample size (n) was a total of (292) cases. sample size calculation was performed using epi info for windows version 7.2

Eligibility criteria:
inclusion criteria: * patients after the first week of their treatment till the end of their treatment protocol and at their follow-up visits * patients who completed esas questioner * male and female patients from 20 -70 years old who are diagnosed with head and neck cancer. exclusion criteria: * patients who didn't start their treatment before the examination * patients who refuse to participate in the study. * patients with leukemia or blood cell cancers, infants and children
ventilator mode and respiratory physiology

Conditions: Pulmonary Disease; Respiratory Failure; Respiratory Effort; Breathing Mechanics

Summary: modern intensive care units (icus) are increasingly adopting newer modes of mechanical ventilation such as adaptive pressure control (apc) modes but there are limited data available regarding risks and benefits of newer modes versus traditional ventilation modes. apc can inadvertently deliver high tidal volumes, which maybe harmful. high tidal volumes may be unrecognized by the provider, due to the complexities of ventilator algorithms and patient interactions. the objective of this aim is to identify risk factors for excess tidal volumes in patients on adaptive pressure control.


Eligibility criteria:
inclusion criteria: * admitted to icu with acute respiratory failure * on adaptive pressure control mode of ventilation * tidal volumes set between 5-8 cc/kg ideal body weight exclusion criteria: * current use of neuromuscular blockade * inability to obtain consent from patient or surrogate decision maker * treating clinician refusal
postprandial blood glucose control with biochaperone® combo and insulin lispro (humalog®) mix 25 in people with type 1 diabetes mellitus

Conditions: Type 1 Diabetes Mellitus

Summary: each subject will be randomly allocated to a sequence of two treatments applied at two separate dosing visits. at each dosing visit subjects will be injected with individualised doses of either biochaperone® combo or humalog® mix 25 immediately before ingesting a standardised mixed meal \[(t=0 min) start of the meal\]. insulin doses will be identical at both dosing visits of one individual and will be administered subcutaneously in the abdominal region. subjects will be asked to consume a standardised meal (e.g. pizza) for dinner at home in the evening before each dosing visit. subjects will attend the clinical site in a fasted state in the morning of each dosing day and stay at the clinical trial centre until 10-hour after dosing (standardised test-meal procedure has been terminated after 6h). the two dosing visits will be separated by a wash-out period of 5-15 days.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus (as diagnosed clinically) \>= 12 months. * treated with multiple daily insulin injections or csii \>= 12 months. * current total daily insulin treatment \< 1.2 (i)u/kg/day. * current total daily bolus insulin treatment \< 0.7 (i)u/kg/day. * usual insulin bolus dose between 0.8 and 2 (i)u per 10 g ch (both inclusive). expecting prandial insulin dose range for standardised meal test between 5 and 12 (i)u. * bmi 18.5-28.0 kg/m\^2 (both inclusive). * hba1c \<= 9.0% by local laboratory analysis * fasting c-peptide \<= 0.3 nmol/l. exclusion criteria: * known or suspected hypersensitivity to trial products or related products. * type 2 diabetes mellitus. * previous participation in this trial. participation is defined as randomised. * participation in any clinical trial within 3 months prior to this trial. * clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the investigator considering the underlying disease. * presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the investigator. * known slowing of gastric emptying and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption. * unusual meal habits and special diet requirements or unwillingness to eat the food provided in the trial. * women of child bearing potential, not willing to use contraceptive methods.
couples' affect in relationships study

Conditions: Depression Disorders

Summary: the goal of this clinical trial is to find out whether learning about well-being impacts the thoughts and feelings of romantic couples. the main question it aims to answer is: * does gaining knowledge about well-being positively impact individuals and their romantic relationships? participants will complete online surveys about their thoughts and feelings.

this study will deliver a meditation-based mobile intervention (the healthy minds program) to one member of a long-term romantic couple and will assess for relationship satisfaction/distress, well-being, and mindfulness in both the primary participant and their partner. the control group will receive a list of well-being-based psychoeducation resources.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * be either married, living together, or in a dating relationship for at least 12 months * proficiency in english * us citizen or permanent resident * if non-monogamous, must be able to enroll in the study with a primary partner with whom they spend the majority of their time. * use of a smartphone (primary participant only) * depression symptoms (≥ 5 on phq-9; primary participant only) exclusion criteria: * severe physical or sexual relationship aggression during the past 6 months (any item endorsement on 5-item severe ipv screener) * endorsement of active suicidality * history of psychosis or mania * prior use of the healthy minds program app * prior significant experience with meditation * severe hearing impairment that would interfere with the use of an audio-based intervention (primary participant only)

Keywords: romantic relationship long-term relationship
molecular biomarkers for sepsis

Conditions: Sepsis; Severe Community-acquired Pneumonia (sCAP); Infection, Bacterial

Summary: this multi-center observational case-control study in intensive care unit (icu) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (scap) -associated sepsis at an earlier stage and predict sepsis-related mortality. patients with scap (cases) will be profoundly characterized over time regarding the development of sepsis and compared with control patients. the mechanisms and influencing factors on the clinical course will be explored with most modern -omics technologies allowing a detailed characterisation. these data will be analysed using machine learning algorithms and multi-dimensional mathematical models.


Eligibility criteria:
inclusion criteria: * admission to the icu of one of the participating centers. * cases: severe community acquired pneumonia with requirement for icu admission. * controls: clinical phenotype of inflammation not due to suspected sepsis in addition, control patients will be patients with fever \>38°c, crp \>100mg/l, no infection focus expected in ≥ 24h. * all required sample types can most likely be collected within the first 24h visits. * expected icu stay of more than 24h. exclusion criteria: * admission to the hospital within the prior 14 days. * patients with psychosis * evidence of a hospital acquired pneumonia. * one of the following respiratory conditions: acute exacerbation of chronic obstructive pulmonary disease (copd) or bronchiectasis, acute severe asthma, aspiration pneumonia, tuberculosis, clinical suspected viral pneumonia without bacterial infection, cardiogenic pulmonary oedema. * patients with an acute respiratory distress syndrome (ards). * patient which can be managed as outpatients and do not require an icu. * patient where a transmission to another institution is likely within the next 24h. * documented rejection of the general consent or participation to research in general. * patients with a palliative situation and a life expectancy due to other diseases (e.g. progressed cancer) less than 28 days.

Keywords: community-acquired pneumonia biomarker clinical data warehouse (cdwh) machine learning data-driven algorithms multi-dimensional modelling sepsis-related mortality streptococcus pneumoniae
one-year effect on levodopa equivalent daily dose of thalamic vim nucleus stimulation compared to subthalamic nucleus stimulation in patients with parkinson's disease

Conditions: Parkinson Disease (PD); Deep Brain Stimulation

Summary: this study compares the effects of deep brain stimulation (dbs) of the thalamic vim nucleus versus the subthalamic nucleus (stn) on the levodopa equivalent daily dose (ledd) in patients with parkinson's disease. the goal is to determine whether vim stimulation, typically used for tremor, can also reduce medication needs. it hypothesizes that stn stimulation leads to greater ledd reduction, but vim may offer moderate benefits in selected case

thesis summary: deep brain stimulation (dbs) is a well-established therapeutic option for patients with advanced parkinson's disease. the two most commonly targeted structures are the subthalamic nucleus (stn) and the ventral intermediate nucleus (vim) of the thalamus. while stn stimulation is known to allow a significant reduction in the levodopa equivalent daily dose (ledd), the effects of vim stimulation on medication dosage remain less clear, particularly in patients selected for predominant tremor. objectives: to compare the evolution of ledd one year after dbs targeting the vim versus the stn in patients with parkinson's disease. to assess whether vim stimulation also enables a meaningful reduction in dopaminergic medication. to contribute to refining surgical indications based on the patient's clinical profile. hypotheses: stn stimulation leads to a greater reduction in ledd compared to vim stimulation. vim stimulation, though primarily used for tremor control, may result in moderate ledd reduction in specific patient profiles. surgical target selection should be personalized, considering not only motor symptom control but also the impact on medication requirements.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease * underwent surgery for subthalamic nucleus (stn) or ventral intermediate nucleus (vim) deep brain stimulation * surgery performed at chru of nancy * surgery performed between 2014 (dxcare implementation) and 2024 exclusion criteria: * no clinical diagnosis of parkinson's disease * no initial dopaminergic treatment * surgery not performed at chru of nancy * death within 1 year following surgery
randomized clinical study comparing two guided surgery techniques for free-end implant placement

Conditions: Dental Implant; Bone Resorption

Summary: this is a randomized multicenter clinical study that compares two static guided surgery techniques in free-end partial edentulism. the aim is to compare the accuracy obtained between dento-osseous supported and dento-mucosal supported surgical splints to place dental implants in posterior osseous ridges.


Eligibility criteria:
inclusion criteria: all patients who come to one of the two clinics mentioned above with a posterior edentulous area from the second premolar onwards and in whom the placement of dental implants is not contraindicated. - exclusion criteria: patients with hypersensitivities or allergies that contraindicate the intervention, presence of orofacial neurological symptoms, patients treated with bisphosphonates, pregnant or breastfeeding women or with contraceptive treatment, signs of infection in the area to be operated, unconventional surgical requirements, or lack of collaboration would be excluded. -

Keywords: guided suergery dental implant partial edentulous
a study to assess the efficacy and safety of pagoclone for adults with stuttering

Conditions: Stuttering

Summary: a multicenter, randomized, 3 arm, placebo-controlled clinical trial to assess the efficacy, safety and tolerability of pagoclone for adults with stuttering.

a multicenter, randomized, 3-arm, placebo controlled, parallel group study with 24 weeks of double blind treatment followed by an 8 week double blind washout and then long-term open-label extension phase.

Eligibility criteria:
inclusion criteria: * male and females age 18 to 80 years presenting with a history of stuttering with onset prior to age 8 years old. * stuttering severity must be notable for \> 3 syllables stuttered on a reading and cenversational task at scereening and with at least 2% contributed individually from conversational and reading tasks. exclusion criteria: * patients with unstable hematological, autoimmune, endocrine, neurological, renal, hepatic, retinal, gastrointestinal, or cardiovascular disease.

Keywords: stutter stuttering adults with a history of stuttering
spironolactone in diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: the aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.


Eligibility criteria:
inclusion criteria: * diabetes mellitus * diabetic nephropathy * glomerular filtration rate \> 30 ml/min/1.73 m2 * blood pressure \> 130/80 mm hg exclusion criteria: * child bearing potential * plasma-potassium \>4.5 mmol/l * breastfeeding * abuse of alcohol or drugs * non-diabetic kidney disease

Keywords: diabetic nephropathy spironolactone aldosterone antagonism renoprotection
assesment of embryo viability and re-expansion after thawing in blastocyst stage embryos

Conditions: Infertility

Summary: in this prospective study, the possible effects of embryo viability and degree of blastocele re-expansion on pregnancy outcomes before vitrified/thawed blastocyst transfer will be evaluated.

thanks to the advances in embryo vitrification technologies in recent years, high embryo viability can be achieved after thawing, and live birth rates increase after the transfer of these embryos. embryo morphology is an essential criterion used to predict embryo viability. blastocysts endure several morphological challenges during vitrification and thawing, including blastocele collapse, cell collapse, and subsequent rehydration. blastocysts usually collapse immediately after thawing. because of these morphological changes, cell damage and loss may occur, and morphological integrity may be impaired. considering that implantation results may be affected due to supraphysiological high estrogen and progesterone levels due to multi follicular development in the ovaries during fresh embryo transfers, the study is planned to be conducted only in patients who have undergone artificial endometrial preparation with hormone replacement therapy. only embryos frozen at the blastocyst stage (day 5) will be included in the study. after embryo thawing, an experienced embryologist will evaluate embryo viability and expansion and record it in the system. approximately 2 hours after the indicated procedure (just before embryo transfer), embryo viability and degree of re-expansion will be re-evaluated by the 2nd experienced embryologist. the evaluation results of both embryologists (embryo viability and re-expansion streams) will be known only to the primary clinician (assoc. prof. şafak olgan). pregnancy results will be learned nine days after embryo transfer, in ultrasonography evaluation three weeks after a positive pregnancy result, a clinical pregnancy will be considered in patients with fetal heartbeat, and morphological differences between the pregnant and non-pregnant groups will be evaluated.

Eligibility criteria:
inclusion criteria: * women aged 18-40 years * frozen- thawed embryo transfer cycles * only the cycles prepared artificially with hormone replacement therapy. * embryos with day 5 (1cc and higher quality) exclusion criteria: * embryos at the cleavage stage (d3) * patients for whom embryo viability and expansion were not evaluated single-blindly by two different embryologists

Keywords: embryo morphology embryo re-expansion frozen- thawed embryo transfer
effect of butorphanol on colonoscopy for patients with postoperative visceral pain

Conditions: Colonoscopy

Summary: the total incidence of abdominal pain after colonoscopy is almost 50%. butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. this clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.


Eligibility criteria:
inclusion criteria: * asa status i-11 * patients performing colonoscopy * sign the informed consent exclusion criteria: * bmi\>30, pregnant * diabetes * depression * patients dependent on opioids * hypertension poorly controlled * serious complications of important organs * obvious abdominal pain before colonoscopy

Keywords: butorphanol, visceral pain, propofol, gastroscopy, colonoscopy
union rate of transverse tibia fracture

Conditions: Closed Transverse Fracture of Shaft of Tibia

Summary: the investigators will compare the three methods of seating a tibial nail - backslapping or backslapping with dynamic locking or internal compression.


Eligibility criteria:
inclusion criteria: * closed tibia shaft fracture treated with an imn exclusion criteria: * unable to consent due to language * unlikely to follow-up for one year